<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04993196</url>
  </required_header>
  <id_info>
    <org_study_id>TSo</org_study_id>
    <nct_id>NCT04993196</nct_id>
  </id_info>
  <brief_title>Quantitative T1rho Magnetic Resonance Imaging in Healthy Subjects</brief_title>
  <official_title>Quantitative T1rho Magnetic Resonance Imaging in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      T1rho imaging is a new MRI technique that has strong potential in neuroimaging. This&#xD;
      technique does not require exogenous contrast agents and has high spatial resolution.&#xD;
&#xD;
      In this study we aim to characterise the normal appearance of T1rho in the brain parenchyma&#xD;
      in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T1rho value in normal grey and white matter in healthy volunteers</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>T1rho value (measured on T1rho weighted MRI) in normal grey and white matter in healthy volunteers</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Magnetic Resonance Imaging</condition>
  <arm_group>
    <arm_group_label>T1rho MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>T1rho imaging</intervention_name>
    <description>Magnetic Resonance Imaging using T1rho</description>
    <arm_group_label>T1rho MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Male and female volunteers greater than or equal to 18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a contraindication to magnetic resonance imaging such as the presence of&#xD;
             metallic implants, claustrophobia and pregnancy.&#xD;
&#xD;
          -  Subjects with previous severe allergic or anaphylactoid reaction to a gadolinium&#xD;
             contrast agent, or contraindication to contrast gadolinium administration, such severe&#xD;
             renal disease or acutely deteriorating renal function, who would be at risk of&#xD;
             nephrogenic systemic fibrosis&#xD;
&#xD;
          -  Subjects who are unable to tolerate the scan without moving the head as a result of&#xD;
             symptoms such as tremor, spasticity, involuntary movements and spasms, cognitive&#xD;
             impairment, coughing, and shortness of breath.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tiffany So</last_name>
    <phone>+85235051035</phone>
    <email>tiffanyso@cuhk.edu.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>CUHK</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany So</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>October 30, 2021</last_update_submitted>
  <last_update_submitted_qc>October 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Professor Tiffany So</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

